UTGIVER AV

 

Utgave for helsepersonell

Det første som skjer etter at du har fått diagnosen, er at legen vil kartlegge tilstanden din.

  • Sist endret: 21.10.2013
  • Sist revidert: 21.10.2013

Vil du vite mer?

Dette dokumentet er basert på det profesjonelle dokumentet "Hiv-infeksjon og aids" i Norsk Elektronisk Legehåndbok. Referanselisten for dette dokumentet vises nedenfor.

Referanser

  1. Folkehelseinstituttet. HIV-situasjonen i Norge per 31. desember 2012. Smittevernboken 2013.
  2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60. NEJM
  3. Huang L, Quartin A, Jones D, Havlir DV. Intensive care of patients with HIV infection. N Engl J Med 2006; 355: 173-81. NEJM
  4. Hammer SM. Management of newly diagnosed HIV infection. N Engl J Med 2005; 353: 1702-10. NEJM
  5. Morris A, Creasman J, Turner J, Luce JM, Wachter RM, Huang L. Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002; 166: 262-7. PubMed
  6. Vincent B, Timsit JF, Auburtin M, et al. Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era. Intensive Care Med 2004; 30: 859-66. PubMed
  7. Narasimhan M, Posner AJ, DePalo VA, Mayo PH, Rosen MJ. Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy. Chest 2004; 125: 1800-4. PubMed
  8. Casalino E, Wolff M, Ravaud P, Choquet C, Bruneel F, Regnier B. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 2004; 18: 1429-33. PubMed
  9. Folkehelseinstituttet. Test og vit. Nov. 2012. http://www.fhi.no/eway/default.aspx?pid=233&t...
  10. Nilsen Ø, Blystad H. Hiv-situasjonen i Norge per 31. desember 2009. MSIS-rapport 17.03.2010.
  11. Aavitsland P, Nilsen Ø. Hivinfeksjon i Norge før 2006. Tidsskr Nor Lægeforen 2006; 126: 3125-30. Tidsskriftet
  12. Bruun JN, Skeie L, Mæland A, Dudman SG, Sannes M, Ormaasen V. Fra dødelig syndrom til kronisk sykdom. Tidsskr Nor Lægeforen 2006; 126: 3121-4. Tidsskriftet
  13. Volmink J. Mother to child transmission of HIV. Clin Evid 2001; 6: 588-95. ClinEvid
  14. The Working Group on MTCT of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America and Europe: results of 13 perinatal studies. J Acquir Immune Defic Syndr 1995; 8: 506-10. PubMed
  15. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362: 2282-94. NEJM
  16. Chasela CS, Hudgens MG, Jamieson DJ, et al. Materanl or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362: 2271-81. NEJM
  17. Bakken Kran A-M, Kvale D. Immunpatogenese og terapeutisk immunisering ved hivinfeksjon. Tidsskr Nor Lægeforen 2006; 126: 3112-6. Tidsskriftet
  18. Fisher M, Benn P, Evans B, et al. UK guidelines for the use of post-exposure prophylaxis for hivfollowing sexual exposure. Int J of ST & AIDS 2006; 17: 81-92.
  19. Perinatal HIV Guidelines Working Group Members. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. http://www.hivatis.org (4.2.2002).
  20. Cooper ER, Charurat M, Mofenson L, Hanson C, Pitt J, Diaz C et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and the prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484 - 94. PubMed
  21. British HIV Association. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. HIV Medicine 2001; 2: 314 - 34. http://www.bhiva.org.
  22. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335: 1621 - 9. NEJM
  23. Nduati R, John G et al. Effect of Breastfeeding and Formula Feeding on Transmission of HIV-1. JAMA 2000; 283:1167-1174. JAMA
  24. Garmark VC, Holmedal SH, Rønsen TK, Bruun JN, Lindemann R, Løkvik BH. HIV-smitte fra mor til barn. Tidsskr Nor Lægeforen 2003; 123: 2029-32. Tidsskriftet
  25. The International Perinatal HIV Group. N Engl J Med 1999; 340: 977-87 NEJM
  26. Ioannidis JPA, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L et al. Pernatal Transmission of Human immunodeficiency Virus Type 1 by Pregnant Women with RNA Loads < 1000 Copies/mL. JID 2001;183:539-45. PubMed
  27. The European Mode of Delivery Collaboration: Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomized clinical trial. Lancet 1999, Mar 27;353:1035-9
  28. Miotti PG, Taha ET, Newton I, et al. HIV transmission through breatfeeding: a study in Malawi. JAMA 1999; 282: 744-9. JAMA
  29. Gerberding JL. Occupational exposure to HIV in health care settings. N Engl J Med 2003; 348: 826-33. NEJM
  30. HIV classification: CDC and WHO staging systems. http://www.aidsetc.org/aidsetc?page=cg-205_hi...
  31. Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis 2004; 38: 1447-53. PubMed
  32. Ormaasen V, Mæland A. Tuberkulose hos HIV-smittede i Norge. Tidsskr Nor Lægeforen 2001; 121: 3425-30. Tidsskriftet
  33. Steinsvoll S, Brokstad Herlofson B. Orale manifestasjoner ved HIV-infeksjon. Tidsskr Nor Lægeforen 2006; 126: 1218-21. Tidsskriftet
  34. Hammer SM, Eron JJ, Reiss P, Schooley RT et al. Antiretroviral Treatment of Adult HIV Infection. 2008. Recommendations of the International AIDS Society-USA Panel. JAMA 2008; 300: 555-70. JAMA
  35. Norsk forening for infeksjonsmedisin. Faglige retningslinjer for oppfølging og behandling av hiv 2013. http://www.oslo-universitetssykehus.no/SiteCo...
  36. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Panel on clinical practices for treatment of HIV infection, mars 2012. http://www.aidsinfo.nih.gov/guidelines/html/1...
  37. European AIDS Clinical Society (EACS). Guidelines version 7.0. October 2013. http://www.eacsociety.org/Portals/0/Guideline...
  38. World Health Organization. Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. Nov 30, 2009. http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf
  39. Treating HIV-infected people with antoretrovirals protects partners from infection. NIH News, may 2011. http://www.niaid.nih.gov
  40. Ormaasen V. Smittevernveileder. Behandling og foerbygging av tuberkulose hos hivsmittede, okt. 2008.
  41. Wilkinson D. Drugs for preventing tuberculosis in HIV infected persons. In: The Cochrane Library, issue 4, 1999. Oxford: Update Software. Cochrane
  42. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomised controlled trials. AIDS 1999; 13: 501-7. PubMed
  43. Trøseid M, Eskesen A, Bruun JN. Immunrekonstitusjonssyndrom ved behandling av hivinfeksjon. Tidsskr Nor Legeforen 2009; 129: 2484-7. Tidsskriftet
  44. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database of Systematic Reviews 2011, Issue 7. Art. No.: CD003510. DOI: 10.1002/14651858.CD003510.pub3. DOI
  45. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software. Cochrane
  46. Goulder PJ, Walker BD. HIV-1 superinfection -- a word of caution. N Engl J Med 2002; 347: 756-8. NEJM
  47. Karim QA, Karim SSA, Frolich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; : DOI:10.1126/science.1193748. DOI
  48. Folkehelseinstituttet. Barnehager og smittevern. Folkehelseinstituttet, januar 2009.
  49. Holm-Hansen C. Vaksiner mot hiv. Tidsskr Nor Lægeforen 2006; 126: 3117-20. Tidsskriftet
  50. Buchbinder S, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-93. PubMed
  51. Bhaskaran K, Mussini C, Antinori A, et al.; CASCADE Collaboration. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63: 213-21. PubMed
  52. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12. PubMed
  53. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 651-81. PubMed
  54. Chu C, Selwyn PA. Complications of HIV infection: a systems-based approach. Am Fam Physician 2011; 83: 395-406. AFP
  55. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2165-74. PubMed
  56. Bonnet F, Balestre E, Thiébaut R et al. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine cohort, France. Clin Infect Dis 2006; 42: 411-7. PubMed
  57. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR Morb Mortal Weekly Rep 2004; 53(RR-15): 1-112.
  58. Rutherford GW, Lifson AR, Hessol NA et al. Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ 1990; 301: 1183-8. BMJ
  59. Ormaasen V, Sandvik L, Dudman SG et al. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population. Scand J Infect Dis 2006: akseptert for publisering.
  60. Bhaskaran K, Hamouda O, Sannes M et al. Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population. JAMA 2008; 300: 51-9. JAMA
  61. Bruun JN. Antivirale midler for reduksjon av mor-til-barn-smitte ved HIV-infeksjon. Tidsskr Nor Lægeforen 2003; 123: 2041-2. Tidsskriftet
  62. Fawzi WW, Msamanga GI, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351: 23-32. NEJM
  63. UNAIDS: 2006 report on the global AIDS epidemic. Genève: WHO, 2006. www.unaids.org/en/HIV_data/2006GlobalReport/default.asp
  64. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921-9. NEJM
  65. Vu SL, Strat YL, Barin F, et al . Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infectous Diseases 2010; : doi:10.1016/S1473-3099(10)70167-5.
  66. Laine C, Markson LE, McKee LJ, Hauck WW, Fanning TR, Turner BJ. The relationship of clinic experience with advanced HIV and survival of women with AIDS. AIDS 1998; 12: 417-24. PubMed
  67. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection. 2010 recommendations of the International AIDS society-USA panel. JAMA 2010; 304: 321-33. JAMA
  68. Ormaasen V, Bruun JN. Antiviral behandling av kronisk HIV-infeksjon hos voksne. Tidsskr Nor Lægeforen 2001; 121: 3414-20. Tidsskriftet
  69. Jordan R, Gold L, Cummins C, Hyde C. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 2002; 324: 757 - 60. BMJ
  70. Perinatal HIV Guidelines Working Group members. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. www.hivatis.org (4.2.2002).
  71. European Commission. Guidelines for treatment of HIV-positive pregnant women and infants. AIDS 2002; 16 (suppl 2): 1 - 24.
  72. European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353: 1035 - 9. PubMed
  73. Castro KG et al.: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Clin Infect Dis 1993; 17: 802-10. PubMed
  74. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200/mm 3
  75. Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365: 1031-1038. PubMed
  76. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292: 251-65. JAMA
  77. Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA 2004; 292: 219-23. JAMA
  78. Rutherford GW, Feldman KA, Kennedy GE. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. The Cochrane Library, Issue 2, 2000. Last amendment 22 February, 2000. Cochrane

Debattregler